{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=16", "query": { "condition": "Immunity Disorders", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 21191, "total_pages": 2120, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T09:50:16.237Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00955591", "title": "Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anal Cancer", "Nonneoplastic Condition", "Precancerous Condition" ], "interventions": [ { "name": "Papanicolaou test", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 48, "start_date": "2009-03-12", "completion_date": "2016-10-14", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-20T09:50:16.237Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00955591" }, { "nct_id": "NCT01084291", "title": "Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dengue Virus" ], "interventions": [ { "name": "Investigational Vaccine for DEN1", "type": "BIOLOGICAL" }, { "name": "Placebo injection", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 18, "start_date": "2010-04", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2013-01-03", "last_synced_at": "2026-10-20T09:50:16.237Z", "location_count": 2, "location_summary": "Burlington, Vermont", "locations": [ { "city": "Burlington", "state": "Vermont" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT01084291" }, { "nct_id": "NCT02537691", "title": "Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FP", "type": "DRUG" }, { "name": "LABA", "type": "DRUG" }, { "name": "LTRA", "type": "DRUG" }, { "name": "LAMA", "type": "DRUG" }, { "name": "Theophylline", "type": "DRUG" }, { "name": "Oral Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 483, "start_date": "2015-08-28", "completion_date": "2017-07-10", "has_results": false, "last_update_posted_date": "2019-04-09", "last_synced_at": "2026-10-20T09:50:16.237Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Mission Viejo, California • Sacramento, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02537691" }, { "nct_id": "NCT04439149", "title": "Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "PI3K-beta Inhibitor GSK2636771", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-05-05", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-10-20T09:50:16.237Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439149" }, { "nct_id": "NCT00001249", "title": "Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, T-Cell", "Lymphoma, T-Cell, Cutaneous" ], "interventions": [ { "name": "Yttrium-90 radiolabeled anti-Tac antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "1989-12", "completion_date": "2000-10", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-20T09:50:16.237Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001249" }, { "nct_id": "NCT07242638", "title": "Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis", "Alopecia Areata" ], "interventions": [ { "name": "Abrocitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 56, "start_date": "2026-01-12", "completion_date": "2029-02-23", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-20T09:50:16.237Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07242638" }, { "nct_id": "NCT03243058", "title": "Low-dose IL-2 in Established T1D - The \"PROREG\" Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1", "Diabetes", "Diabetes, Autoimmune" ], "interventions": [ { "name": "ILT-101 (Aldesleukin; IL-2)", "type": "BIOLOGICAL" }, { "name": "Treatment-Placebo Arm", "type": "OTHER" }, { "name": "Placebo Arm", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Jay S. Skyler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "8 Years to 21 Years" }, "enrollment_count": 0, "start_date": "2023-06", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2024-05-22", "last_synced_at": "2026-10-20T09:50:16.237Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03243058" }, { "nct_id": "NCT05879458", "title": "Ritlecitinib in CTCL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CTCL", "Mycosis Fungoides", "Sezary Syndrome" ], "interventions": [ { "name": "Ritlecitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-05-17", "completion_date": "2025-06-25", "has_results": false, "last_update_posted_date": "2025-07-18", "last_synced_at": "2026-10-20T09:50:16.237Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05879458" }, { "nct_id": "NCT02722148", "title": "Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 24, "start_date": "2016-04-21", "completion_date": "2018-04", "has_results": true, "last_update_posted_date": "2019-04-02", "last_synced_at": "2026-10-20T09:50:16.237Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02722148" }, { "nct_id": "NCT00344448", "title": "Pilot Study of Raptiva to Treat Sjogren's Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sjogren's Syndrome" ], "interventions": [ { "name": "Raptiva", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Dental and Craniofacial Research (NIDCR)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2006-06", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2015-12-21", "last_synced_at": "2026-10-20T09:50:16.237Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00344448" } ] }